Comparative Pharmacology
Head-to-head clinical analysis: AMOXICILLIN CLAVULANATE versus OMNIPEN N.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXICILLIN CLAVULANATE versus OMNIPEN N.
Amoxicillin-Clavulanate vs OMNIPEN-N
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin inhibitors. Clavulanate is a beta-lactamase inhibitor that binds to and inactivates beta-lactamases, protecting amoxicillin from hydrolysis.
Omnipen-N (ampicillin sodium) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby interfering with transpeptidation and resulting in cell lysis.
500 mg/125 mg orally every 8 hours or 875 mg/125 mg orally every 12 hours; intravenous: 1 g/0.2 g every 8 hours.
250-500 mg orally every 6 hours for adults; for severe infections, up to 1 g every 6 hours.
None Documented
None Documented
Amoxicillin: ~1-1.3 hours in adults with normal renal function; Clavulanate: ~1 hour. Both prolonged in renal impairment (amoxicillin up to 7-20 hours with CrCl <10 mL/min).
30-60 minutes (normal renal function); prolonged to 7-10 hours in severe renal impairment (CrCl <10 mL/min).
Amoxicillin: ~60% renal as unchanged drug via glomerular filtration and tubular secretion; Clavulanate: ~30-50% renal as metabolites and unchanged, remainder fecal. Approximately 50-70% of total dose excreted renally within 6 hours.
Primarily renal (80-90% unchanged via tubular secretion); minor biliary/fecal (<10%).
Category C
Category C
Penicillin Antibiotic + Beta-Lactamase Inhibitor
Penicillin Antibiotic